Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
Myelogenous Leukemia, Acute
DRUG: gefitinib
To determine the response rate of Iressa in patients with acute myelogenous leukemia
To determine the safety of Iressa in patients with acute myelogenous leukemia, 2 years|to determine the biologic activity of Iressa in patients with acute myelogenous leukemia, 2 years
Patients will receive Iressa daily until either disease progression or intolerable toxicity develops. On Day 1 of treatment, a physical exam and bloodwork will be performed. Once weekly for the first 8 weeks, a physical exam and complete blood count with differential will be performed.

For the first year, a physical exam, bloodwork will be performed monthly. Bone marrow biopsies will be performed after the first month of therapy and then every 3 months for the first year. After the first year a physical exam, bloodwork will be performed every 3 months and bone marrow biopsies every 6 months.